Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Aurinia Renal Response in Active Lupus With Voclosporin

NCT03021499 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

Conditions Studied

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG Voclosporin

Study Locations (20)

Florida

  • AURORA Investigative Center — Clearwater
  • AURORA Investigative Center — DeBary
  • AURORA Investigative Center — Fort Lauderdale
  • AURORA Investigative Center — Fort Myers
  • AURORA Investigative Center — Miami
  • AURORA Investigative Center — Orlando
  • AURORA Investigative Center — Winter Park

California

  • AURORA Investigative Center — Beverly Hills
  • AURORA Investigative Center — Los Angeles
  • AURORA Investigative Center — Los Angeles
  • AURORA Investigative Center — Palo Alto
  • AURORA Investigative Center — Thousand Oaks
  • AURORA Investigative Center — Torrance

Arizona

  • AURORA Investigative Center — Phoenix
  • AURORA Investigative Center — Phoenix

Colorado

  • AURORA Investigative Center — Aurora
  • AURORA Investigative Center — Denver

Alabama

  • AURORA Investigative Center — Huntsville

Connecticut

  • AURORA Investigative Center — New Haven

Georgia

  • AURORA Investigative Center — Atlanta

Trial Details

FieldValue
Enrollment Target 358 participants
Start Date 2017-05-17
Est. Completion 2019-10-10
Phase Phase 3

Sponsor

Aurinia Pharmaceuticals

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03021499

The ClinicalTrials.gov registry entry for NCT03021499 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 2 interventions — of which Placebo Oral Capsule is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03021499 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03021499 about?

NCT03021499 is a clinical study titled "Aurinia Renal Response in Active Lupus With Voclosporin". The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

What is the current status of trial NCT03021499?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 358 participants. The study started on 2017-05-17. Estimated completion is 2019-10-10.

What conditions does trial NCT03021499 study?

This clinical trial studies the following conditions: Lupus Nephritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03021499?

The interventions under investigation include: Placebo Oral Capsule (DRUG), Voclosporin (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03021499?

This trial is sponsored by Aurinia Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03021499 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial